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Abstract
Background: Ulcerative colitis (UC) is widely viewed as a leukocyte-mediated disorder. Although strong evidence implicates
an exuberant response to microbial components in its pathogenesis, no intrinsic immune defect has been identified and the
underlying pathogenic mechanisms remain obscure.
Methodology/Principal Findings: The acute immune response to bacterial injection was determined in UC patients with
quiescent disease and directly compared to healthy control subjects. Monocyte-derived macrophages were used to
investigate bacterial recognition mechanisms in vitro. An exuberant and protracted acute inflammatory response to bacteria
was evident in patients with UC, which coincides with increased systemic levels of CXCL10. Macrophages stimulated with
bacteria and Toll-like receptor (TLR) ligands revealed a specific defect in the TLR4 response in UC. The defect resulted in the
over-expression of a number of pro-inflammatory molecules under transcriptional control of the adaptor TIR-domain
containing adaptor inducing interferon-b (TRIF).
Conclusion: These findings highlight a dysregulated innate immune response with over-expression of molecules associated
with leukocyte recruitment and activation that may eventuate in the hallmark chronic immune-mediated inflammation of
UC.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease
(IBD) characterised by intermittent florid, continuous superficial
colonic inflammation. It has an incidence of 1 in 1,000 and is
associated with considerable morbidity including an increased
long-term risk of colorectal cancer. UC is most commonly
confined to the rectum or left colon, but involves the whole colon
in 20% of cases. A small proportion of patients (5%) have rectal
sparing and/or backwash ileitis. Aminosalicylates (5-ASA),
corticosteroids and immunomodulators thought to intervene at
various points along the immune and inflammatory cascade are
the mainstay of medical therapy. Colectomy for severe or
recalcitrant disease is required in 20% of patients[1].
It is currently believed that an aberrant innate immune response
to commensal colonic microbiota in genetically susceptible
individuals is a prerequisite for excessive activation of adaptive
immunity within the lamina propria[2]. Although this concept is
supported by extensive evidence from human and animal studies,
neither an intrinsic immune defect nor the underlying mecha-
nism(s) have been identified to date. The pathogenesis of UC
is clearly complex and likely to involve multiple genetic,
environmental and immunological factors[3]. Furthermore, recent
genome wide association (GWA) studies in UC[4,5,6] have
provided few direct clues as to the aetiology. Macrophages are
crucially important in orchestrating innate and adaptive immune
responses to microbes via pattern recognition receptors (TLRs and
NOD-like receptors). These sentinels of the cellular innate
immune system recognise pathogen associated microbial patterns
and mediate diverse immune responses through interconnected,
but subtly distinct, signalling pathways[7]. Colonic microbiota
provide the innate immune system, and specifically TLRs, with the
complex challenge of balancing tolerance and immunological
responsiveness to infection. A dysregulated TLR-mediated innate
immune response may be central to the pathogenesis of UC and
produce the immune cell-mediated inflammation characteristic of
this disease.
In this study, we examined the acute inflammatory response to
bacterial challenge in UC. Using an in vivo model of acute
inflammation, we demonstrate dysregulated innate immunity in
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9891UC with an exuberant, protracted acute inflammatory response to
subcutaneously injected heat killed E.coli (HkEc), with a concurrent
elevation in CXCL10 in the circulation. To elucidate the under-
lying cellular mechanism we then examined cytokine secretion
and gene expression in primary monocyte-derived macrophages
stimulated with HkEc and individual TLR ligands. These in vitro
studies identify a specific defect relating to TLR4, which results in
over-expression of a number of pro-inflammatory molecules
associated with leukocyte recruitment and activation.
Materials And Methods
Ethics Statement
These studies were approved by the Joint UCL/UCLH
Committee for the Ethics of Human Research (project number
04/0324 and 05/Q0505/115). Written informed consent was
obtained from all volunteers.
Subjects
Adult patients with definitive diagnoses of UC confirmed using
standard diagnostic criteria, who met inclusion criteria, were
recruited from the Gastroenterology outpatient clinic at University
College London Hospitals NHS Foundation Trust (UCLH). All
patients had quiescent disease (Mayo score ,3 and serum
inflammatory markers within normal limits) and were on either
no medication or mesalazine alone (#2.4 g/day) at a stable dose
for at least 3 months prior to recruitment. No patient had received
corticosteroid or biological therapy within three months of
inclusion. Healthy controls were approximately matched for age,
sex and smoking history. No subject was studied more than once in
any of the different sets of experiments.
Subcutaneous injection of heat killed E. coli
For bacterial injection experiments, a fully antibiotic-sensitive
clinical isolate of E. coli was grown overnight in minimal citrate
medium supplemented with 1.25 g/L yeast extract (Oxoid), then
killed by heating to 80uC for 30 minutes. Bacteria were washed
twice in sterile PBS, aliquoted, centrifuged and the pellets were
snap-frozen and stored at 270uC. Sterility was confirmed by
culture. Bacteria were resuspended in injection grade normal
saline. Initial dose response was carried out using 2.5610
8,6 610
7,
3610
7, 1.5610
7 and 7.5610
6 E. coli per 100 ml. Four HC subjects
were injected subcutaneously into the volar aspect of each forearm
with four of the doses. From the dose response results all
subsequent studies used 3610
7 per 100 ml. Blood was collected
before and 24, 48 and 72 h after injection, for full blood counts
and measurements of C-reactive protein (CRP) and serum
cytokines (see below). Blood flow was measured at the injection
sites by laser Doppler imaging, and the mean reading of the two
forearms taken (MoorLDI2; Moor Instruments, Axminster, UK).
Serum cytokine measurements
The expression profile of a panel of cytokines in serum samples
collected at 24, 48 and 72 h post inoculation were measured using
the Beadlyte Bio-Plex
TM human cytokine assay (Bio-Rad),
according to the manufacturer’s instructions.
Macrophage isolation and culture and stimulation
Peripheral venous blood was collected from subjects into
syringes containing 5 U/ml heparin. Mononuclear cells were
isolated by differential centrifugation (900 g, 30 minutes, 20uC)
over Lymphoprep and washed twice with sterile phosphate-
buffered saline (PBS; GIBCO, Paisley, UK) at 300 g (5 minutes,
20uC). Cells were resuspended in 10 ml RPMI-1640 medium
(Invitrogen) supplemented with 100 U/ml of penicillin (GIBCO),
100 mg/ml streptomycin (GIBCO) and 20 mM HEPES pH 7.4
(Sigma-Aldrich), and plated at a density of approximately
5610
6 cells/ml in 8 cm
2 NunclonTM Surface tissue culture
dishes (Nunc, Roskilde, Denmark) at 37uC, 5% CO2. After 2 h,
non-adherent cells were discarded and 10 ml of fresh RPMI
supplemented with 10% foetal bovine serum (FBS; Sigma) added
to each tissue culture dish. Cells were then cultured for 5 days at
37uC, 5% CO2, with the addition of a further 10 mls of fresh 10%
FBS/RPMI after 24 h.
Adherent cells were scraped on day 5 and re-plated in 96-well
culture plates at equal densities (10
5/well) in X-Vivo-15 medium
(Cambrex, Walkersville, MD, USA). These primary monocyte-
derived macrophages were incubated overnight at 37uC, 5% CO2
to adhere, and then stimulated for up to 24 h with either 2.5610
5
HkEc, (preparation method same as above), Pam2CSK4 (2 mg/
ml), Pam3CSK4 (2 mg/ml), smooth LPS (sLPS, 200 ng/ml), rough
LPS (rLPS, 200 ng/ml) Poly I:C (125 mg/ml) or flagellin (500 ng/
ml) (Alexis Biochemicals, San Diego, US).
Cytokine secretion assays
Macrophage supernatants were collected after 24 h stimulation
of primary monocyte-derived macrophages with HkEc, Pam2-
CSK4, Pam3-CSK4, sLPS, rLPS, poly I:C or flagellin as described
previously. The expression profile of a panel of cytokines in
macrophage supernatants was measured using the Beadlyte Bio-
Plex
TM human cytokine assay (IL-1Ra, IL-4, IL-5, IL-6, IL-10, IL-
12, IL-13, IL-15, IL-17, G-CSF, GM-CSF, IFN-c, CXCL10 and
MCP-1) (Bio-Rad), according to the manufacturer’s instructions.
IL-8 secretion was measured using commercially available
sandwich ELISA Development kits (R&D Systems, Abingdon,
UK).
TNF-a release was measured using a cytotoxicity bioassay
(obtained from Prof. B. Beutler, The Scripps Institute, CA, USA).
Murine L929 fibroblast cells were grown in DMEM (GIBCO),
supplemented with 10% FBS (Sigma), 100 U/ml of penicillin
(GIBCO) and 100 mg/ml streptomycin (GIBCO), at 37uC, 5%
CO2. A confluent monolayer of murine L929 fibroblasts was
trypsinised and resuspended to 4610
5 cells/ml in DMEM. L929
cells were seeded into 96-well flat bottomed tissue culture plates
(4610
4 cells/well), and incubated overnight at 37uC, 5% CO2.
After overnight culture, the medium was discarded, replaced by
50 ml DMEM containing cyclohexamide (0.04 mg/ml) and
incubated for 20 minutes at 37uC, 5% CO2.5 0ml of cell-free
supernatant (diluted 1:50 in DMEM), collected from primary
macrophages as already described, were added to individual wells.
Serially diluted recombinant human TNF-a (100-0 pg/ml) was
used to determine the standard curve for the assay.
IFN-b release was determined using an L-929 cell line
(4610
5 cells/well) transfected with an IFN-sensitive luciferase
construct (obtained from Prof B. Beutler)[8]. Results expressed as
relative luminescence per ml (rl/ml).
Cytokine release into culture supernatants was normalized for
the numbers of viable cells in each well, ascertained with the MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrozolium bromide,
tetrazolium salt) assay (Boehringer Ingelheim, Berkshire, UK).
20 ml of 2.5 ng/ml MTT was added to each well and incubated
for 4 h at 37uC, 5% CO2. Supernatants were carefully discarded
and 100 ml/well of lysis solution (90% isopropanol, 0.5% sodium
dodecyl sulphate, 0.04 N HCl, 10% H20) added to each well
for 1 h at room temperature. The absorbance was read at
570 nm using a microplate reader (FLUOstar-omega, BMG
labtech, UK).
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Total RNA was prepared from monocyte-derived macrophages
after 4 h stimulation with HkEc, using the RNeasy Mini Kit with
RNase–free DNase treatment (Qiagen GmbH, Hilden, Germany).
Optical density readings were determined for OD260/OD280 and
OD260/OD230 using a NanoDrop ND-1000 spectrophotometer
(Fisher Scientific, Loughborough, UK) to assess protein and
solvent contamination respectively.
Toll-like receptor pathway OligoGEarray chips
Macrophage total RNA was prepared as previously described,
both unstimulated and following incubation with HkEc. Total
RNA (1 mg) was processed to produce biotinylated cRNA targets,
using the TrueLabeling-AMP
TM 2.0 Kit (Superarray Bioscience,
MD, USA), according to the manufacturer’s instructions. Double-
stranded cDNA was synthesized by reverse transcription of twice-
purified mRNA using Truelabeling primers and cDNA Synthesis
Master Mix (Superarray Bioscience, MD, USA). The cDNA was
used as a template to generate biotin-labelled in vitro transcription
products using an Amplification Master Mix (Superarray Biosci-
ence, MD, USA), and biotin-11-UTP (PerkinElmer, MD, USA).
Biotinylated cRNA products were purified using a Superarray
ArrayGrade cRNA Cleanup Kit and quantified using a Nano-
dropH spectrophotometer as previously described. Biotinylated
cRNA (2 mg) was hybridzed to Oligo GEArraysH following
standard Superarray protocol. Microarrays were analyzed using
the manufacturer’s web-based integrated data analysis software
(GEArray Expression Analysis Suite).
Statistical analysis
All data are presented as mean 6 SEM. Statistical significance
between groups was evaluated using an unpaired two-tailed
Student’s t-test. Mean differences were considered significant
when p,0.05.
Results
E. coli challenge in vivo
Previously, one UC patient we studied developed a severe
reaction to injected bacteria with persistent local inflammation
leading to ulceration at both inoculation sites[9]. This reaction
occurred after an injection of 10
9 HkEc, so further studies were
only permissible at the lowest dose capable of eliciting a detectable
response in healthy controls (HC), this corresponded to 3610
7
organisms per inoculation (Figure S1). The subsequent local and
systemic acute inflammatory responses in 21 UC patients and 15
HC subjects (Table S1) were determined.
Local blood flow
The magnitude of the acute inflammatory response was
quantified by measuring elevation in local blood flow following
bacterial challenge. This was maximal in both groups at 24 h,
returning to baseline by 72 h in HC, with no difference in peak
response between patients and controls (Figure 1). UC patients
demonstrated a prolonged response with significantly elevated
blood flow at 48 (p=0.04) and 72 (p=0.002) h. Results were
not significantly different in UC patients with intact colons
(n=16) compared to those that had undergone colectomy (n=5)
(Figure S2). These findings provide strong evidence for an
abnormal systemic inflammatory response to bacteria in UC
patients, mediated by circulating marrow factors rather than
colonic tissue.
Systemic acute phase inflammatory response to E. coli
challenge
The systemic acute phase response was similar in the two
groups: CRP levels were elevated in both and maximal at 48 h
(Figure 2A). White cell and neutrophil counts peaked at 24 h
before returning to baseline after 72 h (Figure 2B, C) in both
groups.
Serum cytokine/chemokine changes after E. coli
challenge
We next measured systemic cytokine/chemokine levels in the
serum (Figure 2 D–F). Circulating CXCL10 levels were signifi-
cantly greater at 48 (p=0.02) and 72 h (p=0.03) after HkEc
inoculation in UC, which coincided with elevated blood flow. IL-6
and MCP-1 levels were not significantly different between the two
groups over the 72 h period. TNF, IFN-c, IL-8, IL-10, IL-13,
IL-17 and MIP-1a were undetectable in serum samples at all
time-points.
Macrophage cytokine release after E. coli stimulation
Our results show a prolonged local inflammatory response with
elevated systemic CXCL10 levels in UC patients following
bacterial stimulation. To investigate these phenomena in more
detail we studied monocyte-derived macrophages from UC
(n=17) and HC (n=11) subjects. Cells were exposed to HkEc
for 24 h and the cytokine/chemokine profile determined (Figure 3).
Release of CXCL10, RANTES, IL-12p70, IL-13 and IL-6 was
significantly elevated in UC. In contrast, no significant differences
were observed in the secretion levels of TNF, GM-CSF, G-CSF,
IFN-c, IL-8, MCP-1, IL-4, IL-5, IL-15, IL-17, IL-10 and IL-1ra
between the two groups. These results provide evidence that
macrophages from UC patients release significantly higher
amounts of a selective group of chemokines/cytokines following
bacterial stimulation.
Macrophage cytokine/chemokine secretion following
TLR stimulation
Whole bacteria are capable of activating a number of
macrophage receptors including TLR and NOD-like receptors.
It is possible that the defective cytokine release is due to an
abnormality in the signalling pathways associated with one or
more of these receptors. Highly purified bacterial-derived TLR
ligands were used to investigate the nature of the defective immune
response to bacteria, these included; rough-LPS (rLPS) (TLR4),
smooth-LPS (sLPS) (TLR4/CD14), Pam3-CSK4 (TLR2/1) Pam2-
CSK4 (TLR2/6) and flagellin (TLR5). Macrophages from UC
patients released significantly elevated levels of CXCL10 following
sLPS and rLPS (Figure 4A). Exposure to Pam3-CSK4, Pam2-
CSK4 and flagellin resulted in low CXCL10 secretion with
equivalent levels in both UC and HC (Figure 4A). The fact that
both sLPS and rLPS resulted in elevated CXCL10 suggests that
the defective TLR4 response is not CD14-dependent. In contrast
to CXCL10, release of IL-8 and TNF-a were not significantly
different in the two groups following stimulation with any of the
TLR ligands (Figure 4B and C). This result suggests that defective
macrophage cytokine secretion in UC results from an abnormality
of TLR4, and not TLR 1, 2, 5 or 6, signalling.
Elevated Type I interferon release downstream of TLR4
TLR4, unlike other TLRs, is unique in its ability to activate
MyD88-dependent and TRIF-dependent signalling pathways[10].
TRIF activates the transcription factor IRF3, which induces genes
that contain interferon-sensitive response elements (ISRE). Genes
Prolonged Inflammation in UC
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a and -b) which are release within hours after TLR stimula-
tion[11]. In order to determine whether the abnormal TLR4
response in UC relates to a defective TRIF pathway, macrophages
were stimulated for 6 h with LPS and Pam3-CSK4 and the level of
IFN-b determined using an ISRE-luciferase reporter assay
(Figure 5). Induction of the MyD88-dependent pathway via
TLR2/1 resulted in minimal IFN-b release in both UC and HC
 
 
 
 
 
   
Figure 1. Local inflammation was protracted in UC patients after subcutaneous injection of HkEc. (A) Blood flow at the injection site was
elevated and prolonged in patients with UC (n=21) at 48 (p=0.04) and 72 h (p=0.002) compared to HC (n=15). (B) Laser Doppler images showing
elevated and prolonged local blood flow in a UC patient after HkEc inoculation (Red represents high and purple low blood flow).
doi:10.1371/journal.pone.0009891.g001
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and MyD88-dependent pathways through TLR4 resulted in the
induction of IFN-b in both HC and UC. Macrophages from UC
subjects released significantly more IFN-b than HC (p=0.00006).
To ascertain whether TRIF-dependent signalling is generally
abnormal in macrophages from UC subjects, we stimulated cells
with poly I:C, a TLR3 ligand (Figure 5). Activation of TLR3,
which results in selective activation of the TRIF-dependent
pathway resulted in release of equivalent levels of IFN-b in HC
and UC, suggesting a TLR4-specific macrophage defect in UC.
 
 
 
 
 
 
 
Figure 2. Systemic CXCL10 levels were elevated in UC patients. Effects of subcutaneous injection of HkEc on, (A) C-reactive protein (all
subjects had baseline CRP levels of ,5 mg/dl), (B) white cell count, (C) circulating neutrophil numbers, (D) CXCL10, (E) MCP and (F) -1 IL-6. TNF-a,
IFN-c, IL-8, IL-10, IL-13, IL-17 and MIP-1a were undetectable in serum samples at all time-points. Results are expressed as a mean 6 SEM (*p,0.05).
doi:10.1371/journal.pone.0009891.g002
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stimulation.
In order to discover if the hyperactive TLR4-TRIF dependent
pathway was still evident when macrophages were exposed to
whole bacteria transcription profiles following HkEc stimulation
for 4 h were studies (Figure 6). We identified significant (p,0.05)
over-expression (fold change .2) of a relatively small group of
TLR-related genes (9 out of 123) in UC (n=8) following
stimulation with HkEc compared to HC (n=8) (Figure 6). The
abnormal gene list included the cytokines IFN-a, IFN-b, IL-
12(p35), IL-10, MCP-1, heat shock protein HSPA6, cyclooxygen-
ase 2 (COX2/PTGS2), as well as the T cell co-stimulatory
molecules CD80 and CD86. The elevation in type I IFN
expression provides evidence that exposure to whole bacterial
results in over-activation of the TLR4-TRIF-dependent pathway.
Interestingly, all of the over-expressed genes have previously been
shown to be induced by TLR4-TRIF-dependent signal-
ing[12,13,11,14,15].
Discussion
In this study we have identified a dysfunctional systemic innate
immune response to bacterial challenge in patients with UC. The
abnormal acute inflammatory response in these patients manifests
as an exuberant and protracted inflammatory response following
bacterial challenge. Detailed in vitro studies identified TLR4 as the
defective bacterial receptor on macrophages, more specifically,
related to regulation of the TRIF-dependent signaling pathway.
Defective signaling resulted in the elevation in type I IFNs as well
as antigen presentation and co-stimulatory genes which have been
associated with leukocyte recruitment and activation. This
abnormal immune response to bacteria may play a role in the
induction of the chronic inflammatory state characteristic of UC.
Although leukocyte-mediated chronic inflammation is a hall-
mark of UC, no intrinsic defect has been identified in leukocytes
from these patients. GWA studies have recently uncovered
susceptibility loci which may play a role in the pathogenesis of
UC[4,5,6]. A high proportion of these contain genes involved in T
cell-mediated immunity[16]. Although this further strengthens the
concept of an aberrant immune response in UC, the pathogenic
mechanism remains unclear. It is becoming increasingly apparent
that UC and Crohn’s disease (the other major inflammatory bowel
disorder) arise from distinctly different immune defects. We have
previously demonstrated an attenuated innate immune response in
Crohn’s which results from diminished cytokine secretion and the
retention of bacteria in the tissue[17,18]. This contrasts entirely
with UC, where acute inflammation is prolonged after bacterial
stimulation. For this reason, the exuberant response in UC
patients is unlikely to be secondary to prior bacterial exposure or
chronic bowel inflammation as the same argument should apply in
Crohn’s disease, in which bowel ulceration and exposure to
coliform bacteria is similar[17].
Raised levels of numerous cytokines and chemokines have
previously been reported in the serum and biopsies of patients with
Figure 3. Pro-inflammatory cytokine secretion by UC macrophages (n=11) in response to HkEc. Results are expressed as a percentage
(mean 6 SEM) of that secreted by HC cells (absolute values for HC shown in Table S1). (*p,0.05, **p,0.01 and ***p,0.001).
doi:10.1371/journal.pone.0009891.g003
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Figure 4. Macrophages from UC patients demonstrate defective cytokine release downstream of TLR4. Macrophages from UC (n=12)
and HC (n=8) were stimulated for 24 h with sLPS (TLR4/CD14), rLPS (TLR4), Pam3CSK4 (TLR2/1), Pam2CSK4 (TLR2/6) and flagellin (TLR5). Secreted
levels of (A) CXCL10, (B) IL-8 and (C) TNF-a were measured. Results are expressed as a mean 6 SEM (**p,0.01, ***p,0.001) (ND = not determined).
doi:10.1371/journal.pone.0009891.g004
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following HkEc injection, only CXCL10 was shown to be
upregulated systemically in UC subjects (the majority of cytokines
were below detectable limits). Local blood flow and CXCL10 were
both significantly elevated at 48 and 72 h post HkEc injection.
CXCL10 is a potent chemoattractant secreted mainly by
monocytes and macrophages within inflamed bowel[22]. CXCR3,
the only known receptor for CXCL10, is present on lymphoid,
epithelial and endothelial cells. CXCR3
+ T cells are activated and
recruited into inflammatory sites by CXCL10 and have been
previously associated with colitis in mice[23,24,25]. Raised
CXCL10 levels have been described both locally in colonic
mucosal biopsies[22], and systemically in serum of patients with
UC[26]. Interestingly, ex vivo studies on colonic biopsies identified
macrophages rather than epithelial cells as the major source of
CXCL10[22]. Our results support the notion that macrophages
exposed to gram-negative bacteria alone have the potential to
cause an exuberant and protracted inflammatory response and
raised CXCL10 levels in UC patients.
Mouse models of colitis provide further support for a pathogenic
role of CXCL10 in UC. CXCL10 and its receptor CXCR3 have
been shown to be upregulated in IL-10 knockout (IL-10
2/2) mice
and those with dextran sulphate sodium (DSS)-induced colitis.
Blockade of the CXCL10-CXCR3 axis with monoclonal anti-
CXCL10 antibodies ameliorates colitis in IL-10
2/2 mice by
decreasing infiltrating T cells[25], and confers protection from
DSS-induced colitis[23]. These findings have resulted in the
development of novel therapeutics which target either CXCL10 or
its receptor CXCR3[24]. A fully humanised anti-CXCL10
monoclonal antibody is currently undergoing phase 2 clinical
trials in active UC.
Our results clearly show that the aberrant macrophage response
to microbial challenge in UC relates specifically to TLR4 pathway
dysregulation. In addition to CXCL10, UC macrophages also
secrete elevated levels of a number of chemokines/cytokines
following both HkEc and LPS stimulation. This contrasts with
normal cytokine secretion following stimulation with other TLR
ligands supporting a TLR4 specific defect in UC. TLR4 is unique
as the only TLR capable of activating both MyD88- and TRIF-
dependent signaling pathways[14]. The signalling defect in UC
seems to lie specifically downstream of TLR4 TRIF-dependent
pathway, with normal MyD88-dependent pathway gene expres-
sion. Stimulation of the TRIF-dependent pathway downstream of
TLR3 results in normal cytokine production confirms a TLR4
TRIF-pathway defect in UC. Increased secretion of type I IFN
could explain the elevation in CXCL10, RANTES, CD80 and
CD86 expression due to IFN receptor (IFNR)-mediated auto-/
paracrine feedback mechanisms[27,28,11,14]. IL-6 and IL-12
expression has been shown to be controlled by a TLR4-TRIF-
dependent/IFNR-independent signal[14]. Collectively these re-
sults suggest UC macrophages possess a defect in the TLR4-TRIF-
dependent pathway that may be amplified by IFNR signalling.
TRIF-dependent genes over-expressed in UC macrophages
following HkEc stimulation, include the Type I IFNs (IFNa1 and
IFNb1) and the T cell co-stimulatory molecules CD80 and
CD86[8]. These molecules have been previously linked to bowel
inflammation. Interestingly, de novo cases of bowel inflammation
resembling UC have been described following recombinant Type I
IFN treatment of chronic hepatitis and multiple sclero-
sis[29,30,31]. Type I IFN therapy have previously been trialed
in UC yielding equivocal results[32,33]. In addition, a direct
pathological role for CD80 and CD86 in UC has been
postulated[34], and blockade of CD80 suppresses colonic
inflammation in a murine colitis model[35]. It is possible that
dysregulated TLR4-TRIF signaling in UC distorts the immune
response to bacteria with pathological consequences. Although the
precise underlying mechanisms controlling the TRIF-dependent
pathway downstream of TLR4 are still unclear, microbial and
Figure 5. TLR4 activation results in an elevation in TRIF signaling and subsequent IFN-b release by macrophage from UC patients.
Macrophages from UC (n=11) and HC (n=7) were stimulated for 6 h with rLPS (TLR4), Pam3CSK4 (TLR2/1) or Poly I:C (TLR3) and the levels of IFN-b
release in determined. Results are expressed as relative luciferase activity (RLA) (mean 6 SEM, ***p,0.001).
doi:10.1371/journal.pone.0009891.g005
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Figure 6. TLR-specific gene transcription profiles reveal increased expression of TRIF-responsive genes in macrophages from UC
patients after stimulation with HkEc. Macrophages from UC (n=8) and HC (n=8) were stimulated for 4 h with HkEc followed by gene array
analysis. (A) Volcano plot showing the alteration in expression levels between UC and HC after HkEc stimulation. Only eight genes (p,0.05 (blue line)
and fold change .2) demonstrated significantly different expression levels after stimulation (labeled a–h). (B) Identification of the abnormally
expressed genes with the corresponding fold change and p-value.
doi:10.1371/journal.pone.0009891.g006
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It is therefore probable that directly targeting molecules associated
with the TRIF-pathway may prove advantageous in the treatment
of UC.
In conclusion, prolonged inflammation and elevated cytokine
release are associated with an abnormal response to bacterial
exposure downstream of TLR4 signalling. Macrophages from
patients with UC have an aberrant TLR4-mediated LPS response
that relates to dysregulated TRIF-dependent gene activation,
resulting in the over-expression of molecules associated with
leukocyte recruitment and activation. The abnormalities identified
might eventuate in the chronic T cell-mediated inflammation that
is a hallmark of UC. Future challenges include further character-
ization of the abnormal TLR4 TRIF-dependent signaling pathway
in UC and identification of the precise molecular defects in UC,
paving the way for novel therapeutics for this debilitating
condition.
Supporting Information
Figure S1 Dose response of local blood flow in HC subjects to a
subcutaneous injection of E. coli.(A) Laser Doppler images of
blood flow levels 24 h post injection. The dose, indicated above
each panel, represents the total amount of bacteria injected. (B)
Change in blood flow at the inoculation site over a 72 h period.
Found at: doi:10.1371/journal.pone.0009891.s001 (2.02 MB EPS)
Figure S2 Comparing the effects of subcutaneous injection of E.
coli on local inflammation in UC patients who have undergone
colectomy surgery (n=5) or have an intact colon (n=16).
Found at: doi:10.1371/journal.pone.0009891.s002 (1.73 MB EPS)
Table S1 HkEc injection study subject demographics;(A)
Cumulative data, (B) HC, (C) UC. (*panproctocolectomy +
ileoanal pouch).
Found at: doi:10.1371/journal.pone.0009891.s003 (1.17 MB EPS)
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